Literature DB >> 15795246

Inhibition of flavivirus infections by antisense oligomers specifically suppressing viral translation and RNA replication.

Tia S Deas1, Iwona Binduga-Gajewska, Mark Tilgner, Ping Ren, David A Stein, Hong M Moulton, Patrick L Iversen, Elizabeth B Kauffman, Laura D Kramer, Pei-Yong Shi.   

Abstract

RNA elements within flavivirus genomes are potential targets for antiviral therapy. A panel of phosphorodiamidate morpholino oligomers (PMOs), whose sequences are complementary to RNA elements located in the 5'- and 3'-termini of the West Nile (WN) virus genome, were designed to anneal to important cis-acting elements and potentially to inhibit WN infection. A novel Arg-rich peptide was conjugated to each PMO for efficient cellular delivery. These PMOs exhibited various degrees of antiviral activity upon incubation with a WN virus luciferase-replicon-containing cell line. Among them, PMOs targeting the 5'-terminal 20 nucleotides (5'End) or targeting the 3'-terminal element involved in a potential genome cyclizing interaction (3'CSI) exhibited the greatest potency. When cells infected with an epidemic strain of WN virus were treated with the 5'End or 3'CSI PMO, virus titers were reduced by approximately 5 to 6 logs at a 5 muM concentration without apparent cytotoxicity. The 3'CSI PMO also inhibited mosquito-borne flaviviruses other than WN virus, and the antiviral potency correlated with the conservation of the targeted 3'CSI sequences of specific viruses. Mode-of-action analyses showed that the 5'End and 3'CSI PMOs suppressed viral infection through two distinct mechanisms. The 5'End PMO inhibited viral translation, whereas the 3'CSI PMO did not significantly affect viral translation but suppressed RNA replication. The results suggest that antisense PMO-mediated blocking of cis-acting elements of flavivirus genomes can potentially be developed into an anti-flavivirus therapy. In addition, we report that although a full-length WN virus containing a luciferase reporter (engineered at the 3' untranslated region of the genome) is not stable, an early passage of this reporting virus can be used to screen for inhibitors against any step of the virus life cycle.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15795246      PMCID: PMC1069577          DOI: 10.1128/JVI.79.8.4599-4609.2005

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  58 in total

Review 1.  Translational control of viral gene expression in eukaryotes.

Authors:  M Gale; S L Tan; M G Katze
Journal:  Microbiol Mol Biol Rev       Date:  2000-06       Impact factor: 11.056

Review 2.  Morpholino antisense oligomers: the case for an RNase H-independent structural type.

Authors:  J Summerton
Journal:  Biochim Biophys Acta       Date:  1999-12-10

3.  Essential role of cyclization sequences in flavivirus RNA replication.

Authors:  A A Khromykh; H Meka; K J Guyatt; E G Westaway
Journal:  J Virol       Date:  2001-07       Impact factor: 5.103

Review 4.  Dengue viral infections; pathogenesis and epidemiology.

Authors:  W J McBride; H Bielefeldt-Ohmann
Journal:  Microbes Infect       Date:  2000-07       Impact factor: 2.700

Review 5.  Morpholino antisense oligomers: design, preparation, and properties.

Authors:  J Summerton; D Weller
Journal:  Antisense Nucleic Acid Drug Dev       Date:  1997-06

6.  Mov34 protein from mouse brain interacts with the 3' noncoding region of Japanese encephalitis virus.

Authors:  M Ta; S Vrati
Journal:  J Virol       Date:  2000-06       Impact factor: 5.103

7.  A novel in vitro replication system for Dengue virus. Initiation of RNA synthesis at the 3'-end of exogenous viral RNA templates requires 5'- and 3'-terminal complementary sequence motifs of the viral RNA.

Authors:  S You; R Padmanabhan
Journal:  J Biol Chem       Date:  1999-11-19       Impact factor: 5.157

8.  Ribavirin inhibits West Nile virus replication and cytopathic effect in neural cells.

Authors:  I Jordan; T Briese; N Fischer; J Y Lau; W I Lipkin
Journal:  J Infect Dis       Date:  2000-08-22       Impact factor: 5.226

9.  Dengue type 4 virus mutants containing deletions in the 3' noncoding region of the RNA genome: analysis of growth restriction in cell culture and altered viremia pattern and immunogenicity in rhesus monkeys.

Authors:  R Men; M Bray; D Clark; R M Chanock; C J Lai
Journal:  J Virol       Date:  1996-06       Impact factor: 5.103

10.  Partial genetic characterization of West Nile virus strains, New York State, 2000.

Authors:  G D Ebel; A P Dupuis; K Ngo; D Nicholas; E Kauffman; S A Jones; D Young; J Maffei; P Y Shi; K Bernard; L D Kramer
Journal:  Emerg Infect Dis       Date:  2001 Jul-Aug       Impact factor: 6.883

View more
  83 in total

1.  Functional analysis of the tick-borne encephalitis virus cyclization elements indicates major differences between mosquito-borne and tick-borne flaviviruses.

Authors:  Regina M Kofler; Verena M Hoenninger; Caroline Thurner; Christian W Mandl
Journal:  J Virol       Date:  2006-04       Impact factor: 5.103

2.  A morpholino oligomer targeting highly conserved internal ribosome entry site sequence is able to inhibit multiple species of picornavirus.

Authors:  Jeffrey K Stone; Rene Rijnbrand; David A Stein; Yinghong Ma; Yan Yang; Patrick L Iversen; Raul Andino
Journal:  Antimicrob Agents Chemother       Date:  2008-03-17       Impact factor: 5.191

3.  Blockade of viral interleukin-6 expression of Kaposi's sarcoma-associated herpesvirus.

Authors:  Yan-Jin Zhang; Rheba S Bonaparte; Deendayal Patel; David A Stein; Patrick L Iversen
Journal:  Mol Cancer Ther       Date:  2008-03       Impact factor: 6.261

4.  Inhibition of primary effusion lymphoma engraftment in SCID mice by morpholino oligomers against early lytic genes of Kaposi's sarcoma-associated herpesvirus.

Authors:  Yan-Jin Zhang; Deendayal Patel; Yuchen Nan; Sumin Fan
Journal:  Antivir Ther       Date:  2011

5.  High-throughput assays using a luciferase-expressing replicon, virus-like particles, and full-length virus for West Nile virus drug discovery.

Authors:  Francesc Puig-Basagoiti; Tia S Deas; Ping Ren; Mark Tilgner; David M Ferguson; Pei-Yong Shi
Journal:  Antimicrob Agents Chemother       Date:  2005-12       Impact factor: 5.191

6.  Development of peptide-conjugated morpholino oligomers as pan-arenavirus inhibitors.

Authors:  Benjamin W Neuman; Lydia H Bederka; David A Stein; Joey P C Ting; Hong M Moulton; Michael J Buchmeier
Journal:  Antimicrob Agents Chemother       Date:  2011-08-08       Impact factor: 5.191

Review 7.  The yellow fever 17D virus as a platform for new live attenuated vaccines.

Authors:  Myrna C Bonaldo; Patrícia C Sequeira; Ricardo Galler
Journal:  Hum Vaccin Immunother       Date:  2014-02-19       Impact factor: 3.452

8.  Identification of novel small-molecule inhibitors of West Nile virus infection.

Authors:  Amine O Noueiry; Paul D Olivo; Urszula Slomczynska; Yi Zhou; Ben Buscher; Brian Geiss; Michael Engle; Robert M Roth; Kyung Min Chung; Melanie Samuel; Michael S Diamond
Journal:  J Virol       Date:  2007-08-22       Impact factor: 5.103

9.  The development, optimization and validation of an assay for high throughput antiviral drug screening against Dengue virus.

Authors:  Pulin Che; Lihua Wang; Qianjun Li
Journal:  Int J Clin Exp Med       Date:  2009-12-08

10.  Recent developments in peptide-based nucleic acid delivery.

Authors:  Sandra Veldhoen; Sandra D Laufer; Tobias Restle
Journal:  Int J Mol Sci       Date:  2008-07-16       Impact factor: 6.208

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.